Recent News

• 05.19.2025 - Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
• 05.15.2025 - Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
• 03.14.2025 - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
• 03.13.2025 - Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
• 03.13.2025 - Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Recent Filings

• 05.16.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - NT 20-F Notification of inability to timely file Form 20-F
• 04.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.28.2025 - EFFECT Notice of Effectiveness
• 03.26.2025 - CORRESP Correspondence
• 03.26.2025 - UPLOAD SEC-generated letter
• 03.25.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership